Esperion reaches settlement agreement with Hetero USA, affiliates

Esperion (ESPR) entered into a settlement agreement with Hetero USA, Inc. and its affiliates Hetero Labs Limited, Hetero Labs Limited Unit-V, and Honour Lab. This agreement resolves the patent litigation brought by Esperion against Hetero USA in response to Hetero USA’ s Abbreviated New Drug Application seeking approval to market a generic version of NEXLETOL prior to the expiration of the applicable patents. Pursuant to the agreement, Hetero USA has agreed not to market a generic version of NEXLETOL in the United States prior to April 19, 2040, unless certain limited circumstances customarily included in these types of agreements occur. The pending patent litigation against the remaining defendants; Dr. Reddy’s Laboratories; MSN Pharmaceuticals is ongoing, and there can be no assurance whether such ongoing patent litigation will allow a generic version of NEXLETOL and/or NEXLIZET, as applicable, to be marketed in the U.S. prior to April 19, 2040.